BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kaneko K, Ito H, Konishi K, Kurahashi T, Ito T, Katagiri A, Yamamoto T, Kitahara T, Mizutani Y, Ohtsu A. Definitive chemoradiotherapy for patients with malignant stricture due to T3 or T4 squamous cell carcinoma of the oesophagus. Br J Cancer. 2003;88:18-24. [PMID: 12556953 DOI: 10.1038/sj.bjc.6600684] [Cited by in Crossref: 65] [Cited by in F6Publishing: 75] [Article Influence: 3.4] [Reference Citation Analysis]
Number Citing Articles
1 Leelayuwatanakul N, Thanthitaweewat V, Wongsrichanalai V, Lertbutsayanukul C, Prayongrat A, Kitpanit S, Sriprasart T. The Prognostic Predictors of Airway Stenting in Malignant Airway Involvement From Esophageal Carcinoma. J Bronchology Interv Pulmonol 2022. [PMID: 35899980 DOI: 10.1097/LBR.0000000000000879] [Reference Citation Analysis]
2 Lee CC, Soon YY, Vellayappan B, Ho F, Tey JCS. Survival rates and safety associated with chemoradiotherapy followed by surgery and chemoradiotherapy alone for patients with T4 esophageal cancer: a systematic review and meta-analysis. Acta Oncol 2022;61:738-48. [PMID: 35450511 DOI: 10.1080/0284186X.2022.2062680] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Pao TH, Chen YY, Chang WL, Chang JS, Chiang NJ, Lin CY, Lai WW, Tseng YL, Yen YT, Chung TJ, Lin FC. Esophageal fistula after definitive concurrent chemotherapy and intensity modulated radiotherapy for esophageal squamous cell carcinoma. PLoS One 2021;16:e0251811. [PMID: 33989365 DOI: 10.1371/journal.pone.0251811] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
4 Chen B, Deng M, Yang C, Dragomir MP, Zhao L, Bai K, Xi M, Hu Y, Zhu Y, Li Q. High incidence of esophageal fistula on patients with clinical T4b esophageal squamous cell carcinoma who received chemoradiotherapy: A retrospective analysis. Radiother Oncol 2021;158:191-9. [PMID: 33667583 DOI: 10.1016/j.radonc.2021.02.031] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
5 Wada Y, Anbai A, Takagi N, Kumagai S, Okuyama E, Nanjo H, Sato Y, Motoyama S, Hashimoto M. Outcomes of Definitive Chemoradiotherapy for Stage IVa (T4b vs. N4) Esophageal Squamous Cell Carcinoma Based on the Japanese Classification System: A Retrospective Single-Center Study. Cancers (Basel) 2020;13:E8. [PMID: 33375169 DOI: 10.3390/cancers13010008] [Reference Citation Analysis]
6 Ohkura Y, Ueno M, Udagawa H. Advantageous factors of R0 curative conversion esophagectomy and the optimal extent of lymphadenectomy after induction therapy for cT4b thoracic esophageal cancer. Ann Gastroenterol Surg 2021;5:204-14. [PMID: 33860140 DOI: 10.1002/ags3.12416] [Reference Citation Analysis]
7 Ohsawa M, Hamai Y, Ibuki Y, Emi M, Okada M. Successful Management of Esophageal Cancer With Perforation Using Bypass Surgery Followed by Definitive Chemoradiotherapy. In Vivo 2020;34:2169-72. [PMID: 32606200 DOI: 10.21873/invivo.12025] [Reference Citation Analysis]
8 Saeki H, Sohda M, Sakai M, Sano A, Shirabe K. Role of surgery in multidisciplinary treatment strategies for locally advanced esophageal squamous cell carcinoma. Ann Gastroenterol Surg 2020;4:490-7. [PMID: 33005843 DOI: 10.1002/ags3.12364] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
9 Chen PJ, Yap WK, Chang YC, Tseng CK, Chao YK, Hsieh JC, Pai PC, Lee CH, Yang CK, Ho AT, Hung TM. Prognostic value of lymph node to primary tumor standardized uptake value ratio in unresectable esophageal cancer. BMC Cancer 2020;20:545. [PMID: 32522275 DOI: 10.1186/s12885-020-07044-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
10 Hu B, Jia F, Zhou H, Zhou T, Zhao Q, Chen Y, Li B, Huang W. Risk Factors Associated with Esophageal Fistula after Radiotherapy for Esophageal Squamous Cell Carcinoma. J Cancer 2020;11:3693-700. [PMID: 32284766 DOI: 10.7150/jca.39033] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
11 Yamasaki M, Yamashita K, Saito T, Tanaka K, Makino T, Miyazaki Y, Takahashi T, Kurokawa Y, Nakajima K, Motoori M, Kimura Y, Mori M, Doki Y. Tracheal resection and anterior mediastinal tracheostomy in the multidisciplinary treatment of esophageal cancer with tracheal invasion. Diseases of the Esophagus 2020;33:doz101. [DOI: 10.1093/dote/doz101] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
12 Furuta M, Yokota T, Tsushima T, Todaka A, Machida N, Hamauchi S, Yamazaki K, Fukutomi A, Kawai S, Kawabata T, Onozawa Y, Yasui H. Comparison of enteral nutrition with total parenteral nutrition for patients with locally advanced unresectable esophageal cancer harboring dysphagia in definitive chemoradiotherapy. Jpn J Clin Oncol 2019;49:910-8. [PMID: 31219161 DOI: 10.1093/jjco/hyz089] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
13 Taniyama TK, Tsuda T, Miyakawa K, Arai H, Doi A, Hirakawa M, Horie Y, Mizukami T, Izawa N, Ogura T, Sunakawa Y, Nakajima TE. Analysis of fistula formation of T4 esophageal cancer patients treated by chemoradiotherapy. Esophagus 2020;17:67-73. [PMID: 31506805 DOI: 10.1007/s10388-019-00691-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
14 Miyata H, Sugimura K, Motoori M, Omori T, Yamamoto K, Yanagimoto Y, Shinno N, Yasui M, Takahashi H, Wada H, Ohue M, Yano M. Clinical Implications of Conversion Surgery After Induction Therapy for T4b Thoracic Esophageal Squamous Cell Carcinoma. Ann Surg Oncol 2019;26:4737-43. [PMID: 31414291 DOI: 10.1245/s10434-019-07727-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
15 Makino T, Yamasaki M, Tanaka K, Miyazaki Y, Takahashi T, Kurokawa Y, Motoori M, Kimura Y, Nakajima K, Mori M, Doki Y. Treatment and clinical outcome of clinical T4 esophageal cancer: A systematic review. Ann Gastroenterol Surg. 2019;3:169-180. [PMID: 30923786 DOI: 10.1002/ags3.12222] [Cited by in Crossref: 12] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
16 Ohkura Y, Ueno M, Iizuka T, Udagawa H. Prognostic Factors and Appropriate Lymph Node Dissection in Salvage Esophagectomy for Locally Advanced T4 Esophageal Cancer. Ann Surg Oncol 2019;26:209-16. [PMID: 30465220 DOI: 10.1245/s10434-018-7074-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
17 Kiyozumi Y, Yoshida N, Ishimoto T, Yagi T, Koga Y, Uchihara T, Sawayama H, Hiyoshi Y, Iwatsuki M, Baba Y, Miyamoto Y, Watanabe M, Matsuyama T, Oya N, Baba H. Prognostic Factors of Salvage Esophagectomy for Residual or Recurrent Esophageal Squamous Cell Carcinoma After Definitive Chemoradiotherapy. World J Surg 2018;42:2887-93. [PMID: 29423738 DOI: 10.1007/s00268-018-4536-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
18 Yamaguchi S, Morita M, Yamamoto M, Egashira A, Kawano H, Kinjo N, Tsujita E, Minami K, Ikebe M, Ikeda Y, Kunitake N, Toh Y. Long-Term Outcome of Definitive Chemoradiotherapy and Induction Chemoradiotherapy Followed by Surgery for T4 Esophageal Cancer with Tracheobronchial Invasion. Ann Surg Oncol 2018;25:3280-7. [PMID: 30051363 DOI: 10.1245/s10434-018-6656-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
19 Sakaguchi M, Maebayashi T, Aizawa T, Ishibashi N, Saito T. Clinical results of multimodality therapy for esophageal cancer with distant metastasis. J Thorac Dis 2018;10:1500-10. [PMID: 29707300 DOI: 10.21037/jtd.2018.03.45] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
20 Park IH, Kim JY. Surveillance or resection after chemoradiation in esophageal cancer. Ann Transl Med 2018;6:82. [PMID: 29666805 DOI: 10.21037/atm.2017.12.16] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
21 Makino T, Yamasaki M, Tanaka K, Tatsumi M, Takiguchi S, Hatazawa J, Mori M, Doki Y. Importance of positron emission tomography for assessing the response of primary and metastatic lesions to induction treatments in T4 esophageal cancer. Surgery 2017;162:836-45. [PMID: 28711321 DOI: 10.1016/j.surg.2017.06.007] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
22 Klevebro F, Ekman S, Nilsson M. Current trends in multimodality treatment of esophageal and gastroesophageal junction cancer - Review article. Surg Oncol. 2017;26:290-295. [PMID: 28807249 DOI: 10.1016/j.suronc.2017.06.002] [Cited by in Crossref: 15] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
23 Ueda H, Takeda M, Ueda S, Kawakami H, Okuno T, Takegawa N, Hayashi H, Tsurutani J, Tamura T, Ishikawa K, Nishimura Y, Nakagawa K. Clinical evaluation of palliative chemoradiotherapy for metastatic esophageal cancer. Oncotarget 2017;8:80286-94. [PMID: 29113302 DOI: 10.18632/oncotarget.17925] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
24 Sun X, Han S, Gu F, Lin G, Wang Z, Wang Y, Xu Y. A Retrospective Comparison of Taxane and Fluorouracil-based Chemoradiotherapy in Patients with Inoperable Esophageal Squamous Cell Carcinoma. J Cancer 2016;7:1066-73. [PMID: 27326249 DOI: 10.7150/jca.13547] [Cited by in Crossref: 4] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
25 Li M, Zhao F, Zhang X, Shi F, Zhu H, Han A, Zhang Y, Kong L, Yu J. Involved-field irradiation in definitive chemoradiotherapy for T4 squamous cell carcinoma of the esophagus. Curr Oncol 2016;23:e131-7. [PMID: 27122981 DOI: 10.3747/co.23.2846] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
26 Li M, Zhang X, Zhao F, Luo Y, Kong L, Yu J. Involved-field radiotherapy for esophageal squamous cell carcinoma: theory and practice. Radiat Oncol 2016;11:18. [PMID: 26846932 DOI: 10.1186/s13014-016-0589-7] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 2.7] [Reference Citation Analysis]
27 Qu X, Biagi J, Banashkevich A, Mercer CD, Tremblay L, Mahmud A. Management and outcomes of localized esophageal and gastroesophageal junction cancer in older patients. Curr Oncol 2015;22:e435-42. [PMID: 26715880 DOI: 10.3747/co.22.2661] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
28 Jingu K, Umezawa R, Matsushita H, Sugawara T, Kubozono M, Yamamoto T, Ishikawa Y, Kozumi M, Takahashi N, Katagiri Y, Kadoya N, Takeda K. Chemoradiotherapy for T4 and/or M1 lymph node esophageal cancer: experience since 2000 at a high-volume center in Japan. Int J Clin Oncol 2016;21:276-82. [PMID: 26324841 DOI: 10.1007/s10147-015-0896-2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis]
29 Shinoda M, Ando N, Kato K, Ishikura S, Kato H, Tsubosa Y, Minashi K, Okabe H, Kimura Y, Kawano T, Kosugi S, Toh Y, Nakamura K, Fukuda H;  Japan Clinical Oncology Group. Randomized study of low-dose vs standard-dose chemoradiotherapy for unresectable esophageal squamous cell carcinoma (JCOG0303). Cancer Sci. 2015;106:407-412. [PMID: 25640628 DOI: 10.1111/cas.12622] [Cited by in Crossref: 76] [Cited by in F6Publishing: 75] [Article Influence: 10.9] [Reference Citation Analysis]
30 Saeki H, Nakashima Y, Zaitsu Y, Tsuda Y, Kasagi Y, Ando K, Imamura Y, Ohgaki K, Ito S, Kimura Y, Egashira A, Oki E, Morita M, Maehara Y. Current status of and perspectives regarding neoadjuvant chemoradiotherapy for locally advanced esophageal squamous cell carcinoma. Surg Today 2016;46:261-7. [PMID: 25740123 DOI: 10.1007/s00595-015-1144-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
31 Zhang P, Xi M, Zhao L, Li QQ, He LR, Liu SL, Shen JX, Liu MZ. Efficacy and prognostic analysis of chemoradiotherapy in patients with thoracic esophageal squamous carcinoma with cervical lymph nodal metastasis alone. Radiat Oncol 2014;9:256. [PMID: 25424871 DOI: 10.1186/s13014-014-0256-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
32 Shimoji H, Karimata H, Nagahama M, Nishimaki T. Induction chemotherapy or chemoradiotherapy followed by radical esophagectomy for T4 esophageal cancer: results of a prospective cohort study. World J Surg 2013;37:2180-8. [PMID: 23649529 DOI: 10.1007/s00268-013-2074-x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 3.1] [Reference Citation Analysis]
33 Karran A, Blake P, Chan D, Reid TD, Davies IL, Kelly M, Roberts SA, Crosby T, Lewis WG. Propensity score analysis of oesophageal cancer treatment with surgery or definitive chemoradiotherapy. Br J Surg 2014;101:502-10. [PMID: 24615406 DOI: 10.1002/bjs.9437] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
34 Minegaki T, Kuwahara A, Yamamori M, Nakamura T, Okuno T, Miki I, Omatsu H, Tamura T, Hirai M, Azuma T, Sakaeda T, Nishiguchi K. Genetic polymorphisms in SLC23A2 as predictive biomarkers of severe acute toxicities after treatment with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma. Int J Med Sci 2014;11:321-6. [PMID: 24578608 DOI: 10.7150/ijms.7654] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
35 Hihara J, Hamai Y, Emi M, Aoki Y, Taomoto J, Miyata Y, Okada M. Esophageal bypass operation prior to definitive chemoradiotherapy in advanced esophageal cancer with tracheobronchial invasion. Ann Thorac Surg. 2014;97:290-295. [PMID: 24200399 DOI: 10.1016/j.athoracsur.2013.08.060] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
36 Saeki H, Morita M, Tsuda Y, Hidaka G, Kasagi Y, Kawano H, Otsu H, Ando K, Kimura Y, Oki E, Kusumoto T, Maehara Y. Multimodal Treatment Strategy for Clinical T3 Thoracic Esophageal Cancer. Ann Surg Oncol 2013;20:4267-73. [DOI: 10.1245/s10434-013-3192-2] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
37 Laquière A, Grandval P, Heresbach D, Prat F, Arpurt JP, Bichard P, D'halluin P, Berthillier J, Boustière C, Laugier R. Self-expanding plastic stent removed after radiochemotherapy for advanced esophageal cancer: Self-expanding plastic esophageal stents. Dis Esophagus 2014;27:176-81. [DOI: 10.1111/dote.12078] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
38 Pimiento JM, Weber J, Hoffe SE, Shridhar R, Almhanna K, Vignesh S, Karl RC, Meredith KL. Outcomes associated with surgery for T4 esophageal cancer. Ann Surg Oncol 2013;20:2706-12. [PMID: 23504118 DOI: 10.1245/s10434-013-2885-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
39 Tamura T, Kuwahara A, Yamamori M, Nishiguchi K, Nakamura T, Okuno T, Miki I, Manabe Y, Sakaeda T. VEGF -634C/G genotype is predictive of long-term survival after treatment with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma. Int J Med Sci 2012;9:833-7. [PMID: 23155356 DOI: 10.7150/ijms.4914] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
40 Miki I, Nakamura T, Kuwahara A, Yamamori M, Nishiguchi K, Tamura T, Okuno T, Omatsu H, Mizuno S, Hirai M, Azuma T, Sakaeda T. THRB genetic polymorphisms can predict severe myelotoxicity after definitive chemoradiotherapy in patients with esophageal squamous cell carcinoma. Int J Med Sci 2012;9:748-56. [PMID: 23136537 DOI: 10.7150/ijms.5081] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
41 Shim HJ, Kim DE, Hwang JE, Bae WK, Nam TK, Na KJ, Cho SH, Chung IJ. A phase II study of concurrent chemoradiotherapy with weekly docetaxel and cisplatin in advanced oesophageal cancer. Cancer Chemother Pharmacol 2012;70:683-90. [PMID: 22932694 DOI: 10.1007/s00280-012-1962-3] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
42 Zhong Z, Gu X, Zhang Z, Wang D, Qing Y, Li M, Dai N. Recombinant human endostatin combined with definitive chemoradiotherapy as primary treatment for patients with unresectable but without systemic metastatic squamous cell carcinoma of the oesophagus. Br J Radiol. 2012;85:e1104-e1109. [PMID: 22898155 DOI: 10.1259/bjr/15321801] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
43 Cwik G, Dąbrowski A, Skoczylas T, Wallner G. The value of ultrasound in the assessment of cervical and abdominal lymph node metastases and selecting surgical strategy in patients with squamous cell carcinoma of the thoracic esophagus treated with neoadjuvant therapy. Adv Med Sci 2011;56:291-8. [PMID: 22119915 DOI: 10.2478/v10039-011-0055-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
44 Reid TD, Davies IL, Mason J, Roberts SA, Crosby TD, Lewis WG. Stage for stage comparison of recurrence patterns after definitive chemoradiotherapy or surgery for oesophageal carcinoma. Clin Oncol (R Coll Radiol) 2012;24:617-24. [PMID: 22386923 DOI: 10.1016/j.clon.2012.02.001] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 1.7] [Reference Citation Analysis]
45 Miyata H, Yamasaki M, Kurokawa Y, Takiguchi S, Nakajima K, Fujiwara Y, Mori M, Doki Y. Clinical relevance of induction triplet chemotherapy for esophageal cancer invading adjacent organs. J Surg Oncol 2012;106:441-7. [PMID: 22371189 DOI: 10.1002/jso.23081] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 3.0] [Reference Citation Analysis]
46 Homs MY, van Oijen MG, Wijnhoven BP, van Hillegersberg R, de Boer-dennert M, Siersema PD. Changes in diagnostic and treatment strategies of oesophageal cancer in the period from 2001 to 2009: a survey in the Netherlands. European Journal of Gastroenterology & Hepatology 2012;24:126-33. [DOI: 10.1097/meg.0b013e32834e7f29] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
47 Semrau R, Herzog SL, Vallböhmer D, Kocher M, Hölscher AH, Müller RP. Prognostic factors in definitive radiochemotherapy of advanced inoperable esophageal cancer. Dis Esophagus 2012;25:545-54. [PMID: 22133297 DOI: 10.1111/j.1442-2050.2011.01286.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
48 Kuwahara A, Yamamori M, Kadoyama K, Nishiguchi K, Nakamura T, Miki I, Tamura T, Okuno T, Omatsu H, Sakaeda T. Effects of plasma concentrations of 5-fluorouracil on long-term survival after treatment with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma. J Exp Clin Cancer Res 2011;30:94. [PMID: 21970688 DOI: 10.1186/1756-9966-30-94] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
49 Ikeda E, Kojima T, Kaneko K, Minashi K, Onozawa M, Nihei K, Fuse N, Yano T, Yoshino T, Tahara M, Doi T, Ohtsu A. Efficacy of concurrent chemoradiotherapy as a palliative treatment in stage IVB esophageal cancer patients with dysphagia. Jpn J Clin Oncol 2011;41:964-72. [PMID: 21742654 DOI: 10.1093/jjco/hyr088] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 2.3] [Reference Citation Analysis]
50 Taniguchi H, Yamazaki K, Boku N, Funakoshi T, Hamauchi S, Tsushima T, Todaka A, Sakamoto T, Tomita H, Machida N, Taku K, Fukutomi A, Onozawa Y, Tsubosa Y, Sato H, Nishimura T, Yasui H. Risk factors and clinical courses of chemoradiation-related arterio-esophageal fistula in esophageal cancer patients with clinical invasion of the aorta. Int J Clin Oncol 2011;16:359-65. [PMID: 21347631 DOI: 10.1007/s10147-011-0192-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 19] [Article Influence: 1.2] [Reference Citation Analysis]
51 Miura A, Honda M, Izumi Y, Kato T, Ryoutokuji T, Kuga G, Karasawa K, Momma K, Fujiwara J, Egashira H, Yoshida M. Induction chemotherapy followed by chemoradiotherapy for T4M0 esophageal cancer. Esophagus 2011;8:31-7. [DOI: 10.1007/s10388-011-0255-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
52 Gwynne S, Hurt C, Evans M, Holden C, Vout L, Crosby T. Definitive chemoradiation for oesophageal cancer--a standard of care in patients with non-metastatic oesophageal cancer. Clin Oncol (R Coll Radiol). 2011;23:182-188. [PMID: 21232928 DOI: 10.1016/j.clon.2010.12.001] [Cited by in Crossref: 72] [Cited by in F6Publishing: 71] [Article Influence: 6.5] [Reference Citation Analysis]
53 Kuwahara A, Yamamori M, Fujita M, Okuno T, Tamura T, Kadoyama K, Okamura N, Nakamura T, Sakaeda T. TNFRSF1B A1466G genotype is predictive of clinical efficacy after treatment with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma. J Exp Clin Cancer Res 2010;29:100. [PMID: 20646319 DOI: 10.1186/1756-9966-29-100] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 1.3] [Reference Citation Analysis]
54 Kuwahara A, Yamamori M, Nishiguchi K, Okuno T, Chayahara N, Miki I, Tamura T, Kadoyama K, Inokuma T, Takemoto Y, Nakamura T, Kataoka K, Sakaeda T. Effect of dose-escalation of 5-fluorouracil on circadian variability of its pharmacokinetics in Japanese patients with Stage III/IVa esophageal squamous cell carcinoma. Int J Med Sci 2010;7:48-54. [PMID: 20151048 DOI: 10.7150/ijms.7.48] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 1.3] [Reference Citation Analysis]
55 Zenda S, Hironaka S, Taku K, Sato H, Hashimoto T, Hasuike N, Boku N, Tsubosa Y, Ono H, Nishimura T. OPTIMAL TIMING OF ENDOSCOPIC EVALUATION OF THE PRIMARY SITE OF ESOPHAGEAL CANCER AFTER CHEMORADIOTHERAPY OR RADIOTHERAPY: A RETROSPECTIVE ANALYSIS. Digestive Endoscopy 2009;21:245-51. [DOI: 10.1111/j.1443-1661.2009.00900.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
56 Kuwahara A, Yamamori M, Nishiguchi K, Okuno T, Chayahara N, Miki I, Tamura T, Inokuma T, Takemoto Y, Nakamura T, Kataoka K, Sakaeda T. Replacement of cisplatin with nedaplatin in a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma. Int J Med Sci 2009;6:305-11. [PMID: 19834547 DOI: 10.7150/ijms.6.305] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 1.5] [Reference Citation Analysis]
57 Sakaeda T, Yamamori M, Kuwahara A, Nishiguchi K. Pharmacokinetics and pharmacogenomics in esophageal cancer chemoradiotherapy. Adv Drug Deliv Rev 2009;61:388-401. [PMID: 19135108 DOI: 10.1016/j.addr.2008.10.005] [Cited by in Crossref: 20] [Cited by in F6Publishing: 25] [Article Influence: 1.5] [Reference Citation Analysis]
58 Takagawa R, Kunisaki C, Makino H, Kosaka T, Ono HA, Akiyama H, Shimada H. Efficacy of chemoradiotherapy with low-dose cisplatin and continuous infusion of 5-fluorouracil for unresectable squamous cell carcinoma of the esophagus. Dis Esophagus 2009;22:482-9. [PMID: 19191850 DOI: 10.1111/j.1442-2050.2008.00935.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
59 Zingg U, Divalentino D, McQuinn A, Mardzuki A, Thompson SK, Karapetis CS, Watson DI. Outcome for esophageal cancer following treatment with chemotherapy and radiotherapy but not esophagectomy: Nonsurgical treatment of esophageal cancer. Clin Exp Gastroenterol 2009;2:75-83. [PMID: 21694830 DOI: 10.2147/ceg.s6273] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
60 Sakaeda T, Yamamori M, Kuwahara A, Hiroe S, Nakamura T, Okumura K, Okuno T, Miki I, Chayahara N, Okamura N, Tamura T. VEGF G-1154A is predictive of severe acute toxicities during chemoradiotherapy for esophageal squamous cell carcinoma in Japanese patients. Ther Drug Monit 2008;30:497-503. [PMID: 18641541 DOI: 10.1097/FTD.0b013e318180e3d2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 13] [Article Influence: 0.2] [Reference Citation Analysis]
61 Zenda S, Hironaka S, Boku N, Yamazaki K, Yasui H, Fukutomi A, Yoshino T, Onozawa Y, Nishimura T. Impact of hemoglobin level on survival in definitive chemoradiotherapy for T4/M1 lymph node esophageal cancer. Dis Esophagus 2008;21:195-200. [PMID: 18430098 DOI: 10.1111/j.1442-2050.2007.00750.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
62 Baba Y, Haga Y, Hiyoshi Y, Imamura Y, Nagai Y, Yoshida N, Hayashi N, Toyama E, Miyanari N, Baba H. Estimation of Physiologic Ability and Surgical Stress (E-PASS system) in patients with esophageal squamous cell carcinoma undergoing resection. Esophagus 2008;5:81-6. [DOI: 10.1007/s10388-008-0153-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
63 Gillham C, Aherne N, Rowley S, Moore J, Hollywood D, O'byrne K, Reynolds J. Quality of Life and Survival in Patients Treated with Radical Chemoradiation Alone for Oesophageal Cancer. Clinical Oncology 2008;20:227-33. [DOI: 10.1016/j.clon.2007.12.002] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
64 Wakatsuki M, Suzuki Y, Nakamoto S, Ohno T, Ishikawa H, Kiyohara H, Kiyozuka M, Shirai K, Nakayama Y, Nakano T. Clinical usefulness of CYFRA 21-1 for esophageal squamous cell carcinoma in radiation therapy. J Gastroenterol Hepatol. 2007;22:715-719. [PMID: 17444861 DOI: 10.1111/j.1440-1746.2006.04498.x] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
65 Okuno T, Tamura T, Yamamori M, Chayahara N, Yamada T, Miki I, Okamura N, Kadowaki Y, Shirasaka D, Aoyama N, Nakamura T, Okumura K, Azuma T, Kasuga M, Sakaeda T. Favorable genetic polymorphisms predictive of clinical outcome of chemoradiotherapy for stage II/III esophageal squamous cell carcinoma in Japanese. Am J Clin Oncol 2007;30:252-7. [PMID: 17551301 DOI: 10.1097/01.coc.0000256059.88247.25] [Cited by in Crossref: 22] [Cited by in F6Publishing: 27] [Article Influence: 1.5] [Reference Citation Analysis]
66 Seto Y, Chin K, Gomi K, Kozuka T, Fukuda T, Yamada K, Matsubara T, Tokunaga M, Kato Y, Yafune A, Yamaguchi T. Treatment of thoracic esophageal carcinoma invading adjacent structures. Cancer Sci 2007;98:937-42. [PMID: 17441965 DOI: 10.1111/j.1349-7006.2007.00479.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 2.1] [Reference Citation Analysis]
67 de Manzoni G, Pedrazzani C, Pasini F, Bernini M, Minicozzi AM, Giacopuzzi S, Grandinetti A, Cordiano C. Chemoradiotherapy followed by surgery for squamous cell carcinoma of the thoracic esophagus with clinical evidence of adjacent organ invasion. J Surg Oncol. 2007;95:261-266. [PMID: 17323341 DOI: 10.1002/jso.20640] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 2.6] [Reference Citation Analysis]
68 Kumekawa Y, Kaneko K, Ito H, Kurahashi T, Konishi K, Katagiri A, Yamamoto T, Kuwahara M, Kubota Y, Muramoto T, Mizutani Y, Imawari M. Late toxicity in complete response cases after definitive chemoradiotherapy for esophageal squamous cell carcinoma. J Gastroenterol 2006;41:425-32. [PMID: 16799883 DOI: 10.1007/s00535-006-1771-8] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 2.5] [Reference Citation Analysis]
69 Fiore FD, Lecleire S, Rigal O, Galais MP, Soussan EB, David I, Paillot B, Jacob JH, Michel P. Predictive factors of survival in patients treated with definitive chemoradiotherapy for squamous cell esophageal carcinoma. World J Gastroenterol 2006; 12(26): 4185-4190 [PMID: 16830371 DOI: 10.3748/wjg.v12.i26.4185] [Cited by in CrossRef: 48] [Cited by in F6Publishing: 50] [Article Influence: 3.0] [Reference Citation Analysis]
70 Di Fiore F, Lecleire S, Galais M, Rigal O, Vié B, David I, Hamidou H, Paillot B, Jacob J, Michel P. Impact of radiation schedule and chemotherapy duration in definitive chemoradiotherapy regimen for esophageal cancer. Gastroentérologie Clinique et Biologique 2006;30:845-51. [DOI: 10.1016/s0399-8320(06)73331-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
71 Elton E. Esophageal cancer. Dis Mon 2005;51:664-84. [PMID: 16458727 DOI: 10.1016/j.disamonth.2005.11.001] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
72 de Manzoni G, Pedrazzani C, Laterza E, Pasini F, Grandinetti A, Bernini M, Ruzzenente A, Zerman G, Tomezzoli A, Cordiano C. Induction Chemoradiotherapy for Squamous Cell Carcinoma of the Thoracic Esophagus: Impact of Increased Dosage on Long-Term Results. The Annals of Thoracic Surgery 2005;80:1176-83. [DOI: 10.1016/j.athoracsur.2005.02.048] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
73 Wallace MB. Stent vs. brachytherapy: does life expectancy help you decide? Gastrointestinal Endoscopy 2005;62:341-3. [DOI: 10.1016/j.gie.2005.06.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
74 Miki I, Tamura T, Nakamura T, Makimoto H, Hamana N, Uchiyama H, Shirasaka D, Morita Y, Yamada H, Aoyama N, Sakaeda T, Okumura K, Kasuga M. Circadian Variability of Pharmacokinetics of 5-Fluorouracil and CLOCK T3111C Genetic Polymorphism in Patients With Esophageal Carcinoma. Therapeutic Drug Monitoring 2005;27:369-74. [DOI: 10.1097/01.ftd.0000162554.23501.e6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.1] [Reference Citation Analysis]
75 Crosby TD, Brewster AE, Borley A, Perschky L, Kehagioglou P, Court J, Maughan TS. Definitive chemoradiation in patients with inoperable oesophageal carcinoma. Br J Cancer. 2004;90:70-75. [PMID: 14710209 DOI: 10.1038/sj.bjc.6601461] [Cited by in Crossref: 76] [Cited by in F6Publishing: 79] [Article Influence: 4.2] [Reference Citation Analysis]